Search

News Facilitated Immunoglobulin Substitution Therapy in Paediatric Patients with Immunodeficiency –⁠ Real-World Data

Patients with humoral immunodeficiency are indicated for immunoglobulin substitution therapy. The study presented below summarizes real-world data concerning the latest substitution method (i.e., facilitated subcutaneous administration) in paediatric patients.

Source: Primary and Secondary Immunodeficiencies 16. 10. 2023

News Treatment of COPD in Individuals with Alpha-1 Antitrypsin Deficiency

A mutation in the gene for alpha-1 antitrypsin (AAT), leading to its deficiency (AATD), causes progressive irreversible destruction of lung tissue. Patients develop chronic obstructive pulmonary disease (COPD) and early emphysema. Several studies evaluating COPD treatment have excluded patients with AATD. The aim of the following systematic literature review was to find and analyze works that include patients with concurrent COPD and AATD and summarize key findings that may form the basis for treatment decisions.

Source: Deficiency of Alpha-1-Antitrypsin 6. 12. 2021

News Evaluation of the m7-FLIPI score in patients with follicular lymphoma revealed a promising predictive biomarker for determining suitable chemotherapy

The authors of a study presented at the December congress of the American Society of Hematology (ASH) in Orlando introduced a new prognostic tool, m7-FLIPI, for determining the risk level of patients with follicular lymphoma (FL). They tested its utility using samples from the GALLIUM clinical trial and, during the analysis, discovered a promising biomarker that could help in selecting the primary chemotherapy for FL patients.

Source: Non-Hodgkin Lymphomas and CLL 27. 1. 2020

News Long-term Efficacy, Safety, and Tolerability of Normal Human IgG with Facilitated Absorption in Patients with Humoral Immunodeficiency

The treatment of patients with humoral immunodeficiency is long-term and therefore needs to be not only effective but also safe and well-tolerated. Below, we present the outcomes from an Italian real-world clinical practice study evaluating the efficacy, safety, and tolerability of human immunoglobulin for facilitated subcutaneous administration and patient satisfaction with this therapy.

Source: Primary and Secondary Immunodeficiencies 12. 1. 2023

News Measurement of Serum Trough Levels of IgG as an Adequate and Beneficial Indicator for Assessing the Pharmacokinetics of Subcutaneously Administered Products

For many patients with primary immunodeficiency, lifelong immunoglobulin substitution is essential to reduce the frequency of severe infections. Subcutaneous home administration is better accepted by patients. However, dosing needs to be customized to the patient. The study presented below may help make therapy individualization easier for doctors and more tolerable for patients.

Source: Primary and Secondary Immunodeficiencies 11. 4. 2023

News Prognostic Model MSKCC in Patients with Metastatic Renal Carcinoma Treated in 1st Line with Sunitinib

A study by Czech authors published in 2020 demonstrated the usefulness of the MSKCC (Memorial Sloan Kettering Cancer Center) model in the prognostic stratification of patients with metastatic renal carcinoma (mRCC) treated with sunitinib in the 1st line. Additionally, a significant difference was found between the outcomes achieved in patients with intermediate risk who had one or two risk factors.

Source: Kidney Carcinoma 6. 12. 2021

News Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients with Hypercholesterolemia –⁠ Meta-Analysis of 35 Randomized Controlled Trials

The authors from several American institutions examined the efficacy and safety of two proprotein convertase subtilisin/kexin type 9 (PCSK9i) inhibitors, alirocumab and evolocumab, in their work. They conducted a systematic meta-analysis of randomized controlled clinical trials comparing the administration of these two PCSK9i with standard treatment.

Source: Hypercholesterolemia 25. 11. 2021

News INTERACTIVE CASE STUDY: Treatment of glaucoma medications without preservatives –⁠ current trend

The use of glaucoma medications without preservatives has been a trend in recent years. You can try their clinical application in the role of a prescribing doctor in an interactive case study. Practical information about this popular local treatment is based on the evidence-based medicine foundation, provided by its author MUDr. Petr Výborný, CSc., from the Eye Clinic of the 1st Faculty of Medicine, Charles University and University Military Hospital in Prague.

Source: Treatment of Glaucoma 28. 9. 2023

News Risk of Venous Thromboembolism and CV Events during Targeted Treatment of Nonspecific Bowel Inflammations

Authors of a freshly published study based on real-world data from the USA investigated whether there are differences in the risk of venous thromboembolism (VTE) and major cardiovascular (CV) events in patients with nonspecific bowel inflammations (IBD) who were newly prescribed the Janus kinase inhibitor (JAK) tofacitinib or the tumor necrosis factor-alpha (TNF-α) inhibitor.

Source: Intestinal Inflammations 22. 8. 2022

Články časopisu Treatment of bleeding caused by liver cirrhosis-associated portal hypertension –⁠ update of Czech Society of Hepatology guidelines

Author of the article: T. Fejfar, T. Vaňásek, R. Brůha, P. Hůlek, V. Procházka, J. Petrtýl, J. Lata Source: Gastroenterologie a hepatologie | 2/2017 21. 4. 2017

News EULAR 2023: What Do CRP Levels Reveal About the Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis?

What is the impact of baseline C-reactive protein (CRP) levels on the efficacy and safety of treating ankylosing spondylitis (AS) with the Janus kinase inhibitor (JAKi) tofacitinib? The authors of the cited study below sought to answer this question, with their results presented at this year’s annual EULAR congress, which took place in Milan, Italy, at the traditional turn of May and June.

Source: Arthritis 22. 8. 2023

News How Common is Alpha-1 Antitrypsin Deficiency?

What is the prevalence of alpha-1 antitrypsin deficiency (AATD)? What comorbidities are associated with it? Are healthcare costs for these patients higher compared to patients with unrelated obstructive lung diseases? Awareness of AATD is low and prevalence data are only indicative. The authors of a study published in the European Respiratory Journal aimed to map this disease in a population of 4 million German insured individuals.

Source: Deficiency of Alpha-1-Antitrypsin 17. 12. 2020

News Intravenous Thrombolysis in Ischemic Stroke Patients on Dabigatran Treatment

What are the outcomes of performing intravenous thrombolysis in patients with acute ischemic stroke after reversing the anticoagulant effect of dabigatran with idarucizumab? The answer is provided by a data analysis from real-world clinical practice in stroke centers, published by Czech authors.

Source: Anticoagulant Treatment 18. 2. 2021

News Is the efficacy of bisoprolol in secondary prevention of acute myocardial infarction in patients after percutaneous coronary intervention comparable to carvedilol?

Beta-blockers (BB) are recommended for all patients after percutaneous coronary intervention (PCI) as part of secondary prevention of acute myocardial infarction (AMI). The study presented below compared the efficacy of carvedilol –⁠ a vasodilating beta-blocker, whose benefit in this indication was confirmed by a randomized clinical trial –⁠ with the effect of bisoprolol.

Source: Cardiovascular Continuum 26. 1. 2021

News Cardiovascular Safety of Tofacitinib in Real-World Clinical Practice –⁠ Results of the STAR-RA Study

Recent results from the ORAL Surveillance clinical trial have raised concerns about the cardiovascular adverse effects of tofacitinib in patients with rheumatoid arthritis. A comprehensive analysis of real-world clinical practice data, involving nearly 13,000 patients, focused on the cardiovascular safety of tofacitinib for this indication.

Source: Arthritis 29. 5. 2022